ZSCAN21

Across TCGA pan-cancer cohorts, ZSCAN21 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZSCAN21 data layer compared with 26 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ZSCAN21 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ZSCAN21 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where ZSCAN21 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	All	1.000	0.682	.002	8	view →
PDAC	DFS	Median	II,III,IV	0.814	0.355	.008	7	view →
LUAD	OS	Quartile	All	0.375	1.000	.031	6	view →
LSCC	OS	Quartile	III,IV	0.565	0.918	.044	2	view →
GBM	OS	Median	All	0.607	0.431	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ZSCAN21–CCRCC (OS)

Open the CCRCC breakdown →